Revenio Group Corporation: The shares issued in Revenio Group Oyj's free share issue and other Annual General Meeting decisions have been entered to the trade register

Revenio Group Corporation, Stock Exchange Release, March 22, 2018 at 9.30

The shares issued in Revenio Group Oyj's free share issue and other Annual General Meeting decisions have been entered to the trade register.

A total of 15.958.812 new shares issued in the free share issue decided upon in Revenio Group Oyj's Annual General Meeting on 20 March 2018 have been entered today in the trade register. The objective of the free share issue is to enhance the liquidity of the company's share. The free share issue applies the pre-emptive right of the shareholders, so that for each old share two new shares will be issued. Thereby, the total number of company's shares after the share issue will be 23.938.218. All shares will give equal shareholder rights. The free share issue will be executed in the book-entry system and does not require any actions by the shareholders. The new shares generate shareholder rights as of today, and will become traded publicly as of 23 March 2018.

REVENIO GROUP CORPORATION

Board of Directors

For further information, please contact:

CEO and President Timo Hildén

tel. +358 40 580 4774

timo.hilden@revenio.fi

www.revenio.fi

DISTRIBUTION:

Nasdaq Helsinki Oy

Financial Supervisory Authority (FIN-FSA)

Principal media

www.revenio.fi

The Revenio Group in brief

Revenio is a Finnish, globally operating health technology corporation whose worldwide success is based on a strongly patented intraocular pressure measurement technology. The Revenio Group consists of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings through preventive health care. Revenio seeks vigorous growth in health technology. Revenio aims to develop even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology is on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process.

In 2017, Revenio Group's net sales totaled EUR 26.8 million, with its operating margin, excluding non-recurring items, standing at 35.5 %. Revenio Group Corporation is listed on Nasdaq Helsinki.